Jenny Zhang

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. doi request reprint The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women
    Jenny Zhang
    Research and Development, Bristol Myers Squibb, Princeton, NJ, USA
    Antivir Ther 16:157-64. 2011
  2. doi request reprint Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir
    Jenny Zhang
    Bristol Myers Squibb, PO Box 5400, Princeton, NJ 08543 5400, USA
    J Antimicrob Chemother 66:2075-82. 2011
  3. doi request reprint Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
    Li Zhu
    Bristol Myers Squibb, Research and Development, Princeton, NJ, USA
    J Antimicrob Chemother 67:465-8. 2012
  4. doi request reprint Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve
    Richard J Bertz
    Bristol Myers Squibb, Research and Development, Princeton, NJ 08543, USA
    Pharmacotherapy 33:284-94. 2013
  5. pmc Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients
    Xiaodong Wang
    Bristol Myers Squibb, Research and Development, Princeton, New Jersey, USA
    AIDS Patient Care STDS 25:509-15. 2011
  6. doi request reprint The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women
    Heather Sevinsky
    Research and Development, Bristol Myers Squibb, Princeton, NJ, USA
    Antivir Ther 16:149-56. 2011
  7. pmc Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients
    Ying Hong
    Discovery Medicine and Clinical Pharmacology, Bristol Myers Squibb, Princeton, New Jersey 08543, USA
    Antimicrob Agents Chemother 55:5746-52. 2011
  8. doi request reprint Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals
    Li Zhu
    Discovery Medicine and Clinical Pharmacology, Bristol Myers Squibb, R and D, Hopewell, NJ, USA
    Antivir Ther 15:1107-14. 2010

Collaborators

  • Timothy Eley
  • Heather Sevinsky
  • Jean Michel Molina
  • Marta Boffito
  • Pablo Tebas
  • Li Zhu
  • Richard Bertz
  • Anna Persson
  • Richard J Bertz
  • Donnie McGrath
  • Ellen Chung
  • Michael Child
  • Ying Hong
  • Xiaodong Wang
  • Dennis Grasela
  • Mark Krystal
  • Awny Farajallah
  • Shanmei Liao
  • Xiaohui Xu
  • Yaoshi Wu
  • Marc Pfister
  • Angela Kashuba
  • Kenneth G Kowalski
  • Kristine Patterson
  • Lisa Mahnke
  • Mariaarantxa Horga
  • Amit Roy
  • Michele Stonier
  • Sheila Breidinger
  • Joan Butterton
  • Wendy Comisar
  • Deborah Panebianco

Detail Information

Publications8

  1. doi request reprint The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women
    Jenny Zhang
    Research and Development, Bristol Myers Squibb, Princeton, NJ, USA
    Antivir Ther 16:157-64. 2011
    ..Raritan, NJ, USA) on the pharmacokinetics (PK) of ethinyl estradiol (EE), norgestimate (NGM), ATV and RTV...
  2. doi request reprint Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir
    Jenny Zhang
    Bristol Myers Squibb, PO Box 5400, Princeton, NJ 08543 5400, USA
    J Antimicrob Chemother 66:2075-82. 2011
    ..This study evaluates an intermittent dosing regimen for rifabutin when it is co-administered with ritonavir-boosted atazanavir...
  3. doi request reprint Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
    Li Zhu
    Bristol Myers Squibb, Research and Development, Princeton, NJ, USA
    J Antimicrob Chemother 67:465-8. 2012
    ..To characterize the pharmacokinetics and inhibitory quotient (IQ) of atazanavir/ritonavir- and lopinavir/ritonavir-based regimens in HIV-infected, treatment-naive patients...
  4. doi request reprint Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve
    Richard J Bertz
    Bristol Myers Squibb, Research and Development, Princeton, NJ 08543, USA
    Pharmacotherapy 33:284-94. 2013
    ....
  5. pmc Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients
    Xiaodong Wang
    Bristol Myers Squibb, Research and Development, Princeton, New Jersey, USA
    AIDS Patient Care STDS 25:509-15. 2011
    ..This supports the current dose recommendations for coadministration of an H(2)-receptor antagonist with atazanavir/ritonavir...
  6. doi request reprint The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women
    Heather Sevinsky
    Research and Development, Bristol Myers Squibb, Princeton, NJ, USA
    Antivir Ther 16:149-56. 2011
    ..Women of childbearing age represent a growing proportion of people living with HIV. Preventing pregnancy is important in HIV-infected women receiving efavirenz as part of their antiretroviral therapy...
  7. pmc Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients
    Ying Hong
    Discovery Medicine and Clinical Pharmacology, Bristol Myers Squibb, Princeton, New Jersey 08543, USA
    Antimicrob Agents Chemother 55:5746-52. 2011
    ....
  8. doi request reprint Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals
    Li Zhu
    Discovery Medicine and Clinical Pharmacology, Bristol Myers Squibb, R and D, Hopewell, NJ, USA
    Antivir Ther 15:1107-14. 2010
    ..Atazanavir plus raltegravir 300/400 mg twice daily is being explored as a ritonavir- and nucleoside-sparing treatment strategy. The pharmacokinetics and safety of this combination in healthy individuals were evaluated...